Title

57例存活二年以上晚期肝癌臨床分析

Translated Titles

Clinical Analysis of 57 Patients with Advanced HCC Survived over Two Years

Authors

周豐(Feng Zhou);倪鎏達(Niu-Da Ni);陳成偉(Cheng-Wei Chen);茹素娟(Su-Juan Ru);傅青春(Qing-Chun Fu);王曉今(Xiao-Jin Wang)

Key Words

晚期肝細胞癌 ; 個體化綜合序貫療法 ; 肝動脈化學栓塞 ; Advanced hepatocellular carcinoma ; Transarterial chemoembolization ; Individualized sequential multi-therapy

PublicationName

肝臟

Volume or Term/Year and Month of Publication

10卷2期(2005 / 06 / 30)

Page #

103 - 104

Content Language

簡體中文

Chinese Abstract

目的 研究多模式治療晚期肝癌長期生存因素。方法 對1990年至2001年收治的372例尚有肝動脈化學栓塞(TACE)指徵的晚期肝癌患者中生存2年以上患者進行回顧性分析,分析包括治療方法在內影響生存率的相關因素。結果 主要影響因素是年齡、腫瘤大小、腫瘤數量、門脈癌栓、肝內外轉移、肝功能Child-Pugh分級、肝臟儲備功能和治療模式。在所有病例中存活2年以上者57例(15.32%),其中行個體化綜合序貫治療占48例(20.25%),9例(6.67%)單用TACE治療。結論 在眾多因素中,個體化綜合序貫治療是改善晚期肝癌患者長期生存的關鍵因素。

English Abstract

Objective To investigate the factors affecting long-term survival rate of patients with advanced hepatocellular carcinoma (HCC). Methods Survival rate was analyzed retrospectively in 372 cases with advanced HCC who received multi-modality therapy from 1990 to 2001. The multi-modality therapy includes transarterial chemoembolization (TACE), immunotherapy, percutaneous ethanol or etherial acid injection and intraabdominal chemotherapy. According to the therapy they were divided into two groups: TACE group and individualized sequential multi-therapy group. Results The 2-year survival rate was 15.32% in the overall patients, 20.25% in individualized sequential multi-therapy group (237 cases), 6.67% in only TACE group (135 cases). The major factors influencing survival were age, extra-hepatic metastases, Child-Pugh classification, hepatic reserved function and methods of treatment (P<0.05). Conclusion Among multiple-factors the individualized sequential, multi-therapy is the key factor in improving the 2-year survival rate of patients with advanced HCC.

Topic Category 醫藥衛生 > 內科